Heather A. Jacene

12.1k total citations · 2 hit papers
152 papers, 5.6k citations indexed

About

Heather A. Jacene is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Heather A. Jacene has authored 152 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Radiology, Nuclear Medicine and Imaging, 58 papers in Pulmonary and Respiratory Medicine and 44 papers in Oncology. Recurrent topics in Heather A. Jacene's work include Medical Imaging Techniques and Applications (48 papers), Radiopharmaceutical Chemistry and Applications (38 papers) and Prostate Cancer Treatment and Research (29 papers). Heather A. Jacene is often cited by papers focused on Medical Imaging Techniques and Applications (48 papers), Radiopharmaceutical Chemistry and Applications (38 papers) and Prostate Cancer Treatment and Research (29 papers). Heather A. Jacene collaborates with scholars based in United States, Canada and France. Heather A. Jacene's co-authors include Richard L. Wahl, Martin A. Lodge, Yvette L. Kasamon, Annick D. Van den Abbeele, Christopher G. Sakellis, James Engles, Sree Harsha Tirumani, Shingo Baba, Philippe Armand and Lawrence H. Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Heather A. Jacene

138 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

2009 2.7k citations Richard L. Wahl, Heather A. Jacene et al. profile →
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

2016 305 citations Heather A. Jacene et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heather A. Jacene United States	30	3.3k	1.8k	1.7k	737	699	152	5.6k
Andrew Quon United States	39	2.6k 0.8×	2.0k 1.1×	1.4k 0.8×	580 0.8×	675 1.0×	114	4.8k
Ur Metser Canada	40	2.8k 0.9×	2.2k 1.2×	1.3k 0.8×	778 1.1×	1.4k 1.9×	220	5.6k
Françoise Kraeber‐Bodéré France	40	2.7k 0.8×	1.0k 0.6×	1.4k 0.8×	823 1.1×	692 1.0×	215	4.9k
Paolo Castellucci Italy	45	3.0k 0.9×	3.6k 2.0×	1.3k 0.7×	694 0.9×	648 0.9×	194	6.0k
Eric Rohren United States	35	2.2k 0.7×	1.6k 0.9×	1.1k 0.6×	543 0.7×	885 1.3×	132	4.4k
Tim Akhurst Australia	29	2.1k 0.6×	2.4k 1.3×	1.3k 0.7×	409 0.6×	858 1.2×	67	4.1k
Jörg Kotzerke Germany	36	3.0k 0.9×	1.9k 1.0×	870 0.5×	304 0.4×	624 0.9×	181	4.8k
Yvette L. Kasamon United States	34	2.3k 0.7×	1.1k 0.6×	2.1k 1.2×	980 1.3×	357 0.5×	99	5.9k
Elif Hindié France	44	3.0k 0.9×	1.5k 0.8×	1.3k 0.8×	470 0.6×	1.4k 2.0×	212	5.8k
Ludwig G. Strauss Germany	37	3.1k 1.0×	1.6k 0.9×	1.3k 0.8×	272 0.4×	588 0.8×	147	5.3k

Countries citing papers authored by Heather A. Jacene

Since Specialization

Citations

This map shows the geographic impact of Heather A. Jacene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather A. Jacene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather A. Jacene more than expected).

Fields of papers citing papers by Heather A. Jacene

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather A. Jacene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather A. Jacene. The network helps show where Heather A. Jacene may publish in the future.

Co-authorship network of co-authors of Heather A. Jacene

This figure shows the co-authorship network connecting the top 25 collaborators of Heather A. Jacene. A scholar is included among the top collaborators of Heather A. Jacene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather A. Jacene. Heather A. Jacene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Richard J., Philip J. Saylor, Xin Gao, et al.. (2025). Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer. Practical Radiation Oncology. 15(6). e597–e605. 4 indexed citations

Ravi, Praful, Katherine K. Perez, Wanling Xie, et al.. (2025). 2416P Prevalence, clonal dynamics and clinical impact of clonal hematopoiesis (CH) in patients (pts) receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 36. S1228–S1228.

Xie, Wanling, John F. Gallagher, Andrew F. Voter, et al.. (2025). Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer. Cancers. 17(12). 1960–1960. 1 indexed citations

Morgan, Todd M., Stephen A. Boorjian, Mark K. Buyyounouski, et al.. (2024). Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. The Journal of Urology. 211(4). 526–532. 13 indexed citations

Groheux, David, Sofia C. Vaz, Philip Poortmans, et al.. (2024). Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. The Breast. 78. 103806–103806. 2 indexed citations

Gatsonis, Constantine, Heather A. Jacene, Roisín M. Connolly, et al.. (2024). Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.. Journal of Clinical Oncology. 42(16_suppl). TPS614–TPS614.

Vaz, Sofia C., J.P. Pilkington Woll, Fátima Cardoso, et al.. (2024). Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 51(9). 2706–2732. 30 indexed citations

Choudhury, Atish D., Hyewon Hyun, Emma Kelly, et al.. (2024). Patient outcomes after therapy with ¹⁷⁷Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.. Journal of Clinical Oncology. 42(4_suppl). 87–87. 1 indexed citations

Mehrtash, Alireza, Erik Ziegler, Bhanusupriya Somarouthu, et al.. (2023). Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision. Computerized Medical Imaging and Graphics. 111. 102312–102312. 2 indexed citations

10.

Hope, Thomas A., Samuel A. Mehr, Michael J. Morris, et al.. (2023). ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA. Endocrine Abstracts. 1 indexed citations

11.

Mario, Julia, et al.. (2023). Hepatobiliary Scintigraphy: A Case-based Review. Radiographics. 43(9). e220104–e220104. 1 indexed citations

12.

Sakellis, Christopher G. & Heather A. Jacene. (2022). Imaging for Radiation Planning in Breast Cancer. Seminars in Nuclear Medicine. 52(5). 542–550. 1 indexed citations

13.

Akin, Esma A., et al.. (2022). Interim FDG-PET/CT for Response Assessment of Lymphoma. Seminars in Nuclear Medicine. 53(3). 371–388. 9 indexed citations

14.

Wrenn, Sean M., Alessandra L. Moore, Justine A. Barletta, et al.. (2022). Higher SUVmax on FDG-PET is associated with shorter survival in adrenocortical carcinoma. The American Journal of Surgery. 225(2). 309–314. 5 indexed citations

15.

McKay, Rana R., Dominick Bossé, Kathryn P. Gray, et al.. (2018). Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research. 24(17). 4081–4088. 26 indexed citations

16.

Jacene, Heather A., Yvette L. Kasamon, Richard F. Ambinder, et al.. (2016). Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Molecular Imaging and Biology. 19(3). 429–436. 10 indexed citations

17.

Warren, Laura, Hao Guo, Meredith M. Regan, et al.. (2015). Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Research and Treatment. 151(1). 225–232. 21 indexed citations

18.

Warren, Laura, Hao Guo, Meredith M. Regan, et al.. (2015). Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Annals of Surgical Oncology. 22(8). 2483–2491. 26 indexed citations

19.

Pyo, Junhee, Kyung Won Kim, Heather A. Jacene, et al.. (2013). End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis. Clinical Cancer Research. 19(23). 6566–6577. 15 indexed citations

20.

Jacene, Heather A., Ross W. Filice, Wayne Kasecamp, & Richard L. Wahl. (2007). Comparison of 90 Y-ibritumomab tiuxetan and 131 I- tositumomab in clinical practice. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact